Construction method of mouse hyperuricemia model
Through the combined use of yeast extract, hypoxanthine and potassium oxyazine and HPLC detection methods, the stability and uric acid detection problems in the construction of the hyperuricemia model in mice were solved, and real-time monitoring and accurate detection of uric acid content were achieved. , provides a cost-effective hyperuricemia model suitable for drug development and pathological research.
Patent Information
- Application Number
- CN202410957270.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-26
AI Technical Summary
The existing model construction method for hyperuricemia in mice has problems such as unstable modeling, difficult uric acid detection and high cost, especially the difficulty in monitoring changes in uric acid content in real time, resulting in inaccurate drug identification results.
Yeast extract, hypoxanthine and potassium oxyazine were used as molding agents, and the modeling test was carried out for 14 to 21 days through gavage and intraperitoneal injection, and blood uric acid content was tested every week, and micro-purpose using HPLC method. Blood invasion and uric acid testing have broken through the limitations of traditional blood invasion.
The stable construction of the mouse hyperuricemia model and real-time monitoring of uric acid content were achieved, which reduced experimental error and cost, and provided a hyperuricemia renal injury model that meets clinical characteristics, suitable for the study of drug screening and pathological mechanism research. .
Smart Images

Figure CN119014365A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biological models, and in particular to a method for constructing a mouse hyperuricemia model. Background Art
[0002] Hyperuricemia has become a global public health problem. It is the "fourth highest" after hypertension, diabetes, and hyperlipidemia. The prevalence rate is increasing year by year, and the incidence rate has tended to be younger. Therefore, the prevention and treatment of hyperuricemia has also become a hot topic in current research. If we want to explore the efficacy of drugs, we cannot avoid exploring and discussing the effects in the body. However, in terms of animal experiments, such as rodent experimental subjects, they are interfered by unstable factors, causing research resistance and affecting the results of drug identification. Regarding animal experimental subjects, due to the large difference in physiological structure between poultry and humans and the long breeding cycle, they are not commonly used; rodent mice have become a commonly used animal model because of their low price, simple breeding, fast breeding speed and drug sensitivity. However, the difficulty lies in the fact that rodents such as mice have a gap with human uric acid metabolism. They still have uricase expression in their bodies, which will convert uric acid into more soluble allantoin and excrete it out of the body, making it difficult for uric acid to accumulate in the body, which increases the difficulty of creating HUA models. Therefore, if mice and rats are to be used as model animals, in order to make up for the gap caused by uricase, uricase inhibitors are needed to reduce their activity so that uric acid can accumulate in the body, thereby narrowing the gap between uric acid metabolism in humans.
[0003] Hyperuricemia is a common metabolic disease, which refers to the disorder of purine metabolism, the imbalance between endogenous production and excretion - uric acid (UA) levels are higher than normal, and abnormal uric acid is the main clinical manifestation. Clinically, it is mainly divided into two categories: primary and secondary. Primary is divided into two reasons: one is that the body itself produces too much uric acid due to problems with related enzyme synthesis, and the other is that uric acid cannot be metabolized normally due to kidney defects, accumulating in the body to cause high uric acid; secondary is mainly caused by some external factors that cause excessive synthesis or insufficient metabolism of uric acid, such as disease, high-purine diet and drug side effects. The cause of the disease studied in this mouse model is secondary. The accumulation of uric acid in the body caused by acquired dietary habits is closer to the cause of disease in most people: This article uses three methods of gavage yeast extract, hypoxanthine and the combination of two drugs to establish a hyperuricemia mouse model. It should be noted that all three methods need to be supplemented with intraperitoneal injection of potassium oxonate to achieve the purpose of being closest to the human uric acid metabolism method. Potassium oxazoline belongs to the triazine compound class. Its chemical structure is similar to the purine ring of uric acid, so it can bind to uricase. It is a selective competitive inhibitor of uricase and can reduce the decomposition of uric acid.
[0004] Regarding the verification of whether the model is successful, the serum uric acid value is mainly used as a reference. However, there are certain difficulties in the detection of uric acid at present - there is a lack of online detection methods, and it is impossible to monitor the success of the model in real time. This is mainly because the existing uric acid detection methods require a large amount of blood. A single large amount of blood will cause the death of mice. A batch of mice can only be tested once, which is extremely accidental. There is no way to accurately monitor the serum uric acid content of mice in different time periods in real time. After drug treatment, uric acid is metabolized faster and will exert its efficacy within 0.5h to 3h after administration. If the test results cannot be analyzed in time, it will be unfavorable for the analysis of pharmacokinetic and pharmacodynamic results.
[0005] Existing inventions have constructed some hyperuricemia animal models. Patent "A method for constructing an acute hyperuricemia animal model" (CN106619692B), patent "A method for constructing an acute hyperuricemia rat model" (CN107441112A), patent "A method for constructing an acute hyperuricemia tree shrew model" (CN107536846A) only use one drug for modeling and do not use uricase inhibitors on rodents, which is not scientific enough; patent "A method for constructing a spontaneous hyperuricemia mouse model and its use" (CN104388467A), patent "A hyperuricemia rat model and its construction method" (CN111418553A) use gene editing technology for modeling. Such methods are expensive, have high technical requirements, are not universal and difficult to promote, and gene knockout mice have hyperuricemia. The causes of secondary hyperuricemia in humans are quite different, which is not conducive to the development of uric acid-lowering drugs; although the patent "A method for constructing a hyperuricemia model" (CN106900652B), the patent "A method for replicating a rat model of persistent hyperuricemia" (CN108030784A), and the patent "A method for constructing an acute hyperuricemia mouse model" (CN111887202A) use a combination of multiple drugs and take into account the expression of uricase in rodents, the administration method is to allow them to eat and drink freely in the form of feed and water. This method is difficult to avoid the difference in the amount of food intake of each animal, which is not rigorous enough. More importantly, these methods have not established a live blood uric acid detection method for mouse models, and cannot monitor the serum uric acid content of mice, and cannot accurately judge the modeling situation. Traditional modeling methods may have large errors, high contingency, and high cost. More importantly, it is difficult to judge the uric acid content of the modeling. After the model is completed, the mice may be killed and the uric acid tested, and the results may not meet the characteristics of hyperuricemia, which can easily cause a waste of time, manpower and material resources.
[0006] At present, hypoxanthine and potassium oxonate are commonly used drugs for modeling. The commonly used modeling detection method is to continuously administer the drugs for a period of time, then kill the mice to collect blood and test the serum for uric acid. However, the combination of the two drugs lacks stability, and the uric acid in the same mouse can only be tested once, which has a great possibility of error and contingency, and lacks scientificity. Summary of the invention
[0007] The purpose of the present invention is to solve the above-mentioned technical problems and to provide a method for constructing a mouse hyperuricemia model with a stable modeling effect and capable of timely monitoring changes in the uric acid content of mice.
[0008] To achieve the above object, the present invention provides a method for constructing a mouse hyperuricemia model comprising the following steps:
[0009] Using yeast extract, hypoxanthine and potassium oxonate as modeling agents, the experimental mice were subjected to a modeling experiment lasting 14 to 21 days to obtain a hyperuricemia mouse model;
[0010] During the modeling experiment, the blood uric acid content of the experimental mice was tested every week.
[0011] Furthermore, the dosage of the yeast extract is 5-10 g / kg·d, the dosage of hypoxanthine is 300-600 mg / kg·d, and the dosage of potassium oxonate is 280-320 mg / kg·d.
[0012] Furthermore, the yeast extract and hypoxanthine are both administered by oral gavage once a day; and the potassium oxonate is administered by intraperitoneal injection once a day.
[0013] Furthermore, before oral administration, the yeast extract and hypoxanthine are prepared into a suspension using sodium carboxymethyl cellulose aqueous solution as solvent, and the volume concentration of the suspension is 70-80 mg / mL, wherein the suspension contains 35-40 mg / mL hypoxanthine and 0.583-0.667 g / mL yeast extract.
[0014] Furthermore, before the potassium oxonate is administered by intraperitoneal injection, the potassium oxonate is prepared into a potassium oxonate suspension using a sodium carboxymethyl cellulose aqueous solution as a solvent, and the volume concentration of the potassium oxonate suspension is 50 to 70 mg / mL.
[0015] Furthermore, the mass concentration of sodium carboxymethyl cellulose in the sodium carboxymethyl cellulose aqueous solution is 0.3-0.8%.
[0016] Furthermore, the experimental mice are SPF grade male Kunming mice, weighing 18 to 30 g;
[0017] The feeding conditions of the experimental mice are as follows: the feeding environment temperature is 22-26° C., and the feeding environment humidity is 50-70%.
[0018] Furthermore, the specific process of the blood uric acid content detection is:
[0019] Performing minimally invasive blood sampling on the tail of the test mouse to obtain a blood sample, and then centrifuging the blood sample to obtain a sample to be tested;
[0020] The uric acid of the samples was detected by HPLC.
[0021] Furthermore, the specific operation process of performing minimally invasive blood sampling on the tail of the test mouse to obtain a blood sample, and then centrifuging the blood sample to obtain the sample to be tested is as follows:
[0022] The experimental mice were fasted but not watered for 12 to 18 hours before blood collection. After the modeling agent was given for 1 to 2 hours, the experimental mice were fixed, the middle part of the tail was disinfected with alcohol, and the tail vein was punctured with a needle after evaporation. The direction of needle insertion was from the tip of the mouse tail to the base. 15 to 30 μL of blood sample was drawn into the first centrifuge tube weighed in advance with a 10 μL pipette. The first centrifuge tube was centrifuged at 12000 to 14000 rpm for 10 to 20 minutes and boiled in water for 10 to 20 minutes. The blood was obtained after instant centrifugation. Clear A, add 3 to 4 times the volume of distilled water of serum A to the first centrifuge tube, vortex for 2 to 4 minutes, centrifuge at 12000 to 14000 rpm for 10 to 20 minutes, draw 30 to 50 μL of sample B into the second centrifuge tube, add phenol chloroform with the same volume as sample B, vortex mix for 2 to 4 minutes, centrifuge at 12000 to 14000 rpm for 10 to 20 minutes to obtain supernatant C, transfer supernatant C to the injection vial containing the inner insert to obtain the sample to be tested.
[0023] Furthermore, the specific parameters for the HPLC method for uric acid detection of the sample to be tested are as follows:
[0024] Chromatographic conditions: C18 column, detection wavelength set at 270-290 nm, flow rate 0.8-1.2 mL / min, column temperature 30°C, injection volume 18-20 μL; mobile phase is water-methanol system, phase A: 95% water, 5% methanol, 0.1% acetic acid; phase B: 100% methanol, 0.1% acetic acid; gradient elution program is shown in Table 1:
[0025] Table 1 HPLC program elution conditions
[0026]
[0028] Yeast extract is rich in purine, protein and other ingredients and has rich taste levels, which can reduce the irritation of simple hypoxanthine on the oral cavity and digestive tract of mice and the phenomenon of mice's refusal to eat, and enhance the absorption efficiency of mice for purine compounds; at the same time, yeast extract is rich in various purine compounds, which can provide substrate raw materials in each link of mice's metabolism of uric acid and enhance the efficiency of uric acid biosynthesis; purine-rich yeast extract better simulates human high-purine foods such as beer and seafood, so the induced secondary hyperuricemia is more valuable for reference.
[0029] The present invention performs minimally invasive blood sampling from the tail of mice. Although the amount of blood sampled is extremely small, the change of blood uric acid content can still be detected by the HPLC uric acid detection method, which breaks through the traditional large-scale traumatic blood sampling such as killing, tail cutting, and eye removal, which causes irreversible damage to mice and interferes with experimental results.
[0030] HPLC method for detecting uric acid: small sample volume (15-30 μL serum); compared with traditional biochemical detection, it has higher specificity and accuracy after chromatographic purification and comparison with standards, eliminating interference from impurities; its detection limit (0.92 μmol / L), quantification limit (1.70 μmol / L), sample recovery rate (88.66%-105.61%), and relative standard deviation (9.31%).
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] 1) Using mice as model animals, their serum uric acid levels are comparable to those of hyperuricemia patients, and their serum uric acid levels are stable and reproducible;
[0033] 2) The modeling experiment was conducted on experimental mice using yeast extract and hypoxanthine, which increase the uric acid precursors for a long time, and the uricase inhibitor potassium oxonate. Through the synergistic effect of the three modeling agents, a model similar to the pathogenesis of hyperuricemia in the human body was prepared. A reasonable and stable hyperuricemia renal damage mouse model that meets clinical characteristics can be successfully established in 14 to 21 days;
[0034] 3) An in vivo HPLC method for detecting uric acid in mouse blood was constructed, which can monitor the serum uric acid content of mice in real time, breaking through the traditional methods of blood extraction by major trauma such as killing, tail cutting, and eye removal, which can cause irreversible damage to mice and interfere with the experimental results. The secondary hyperuricemia model obtained by this method meets the clinical characteristics of hyperuricemia renal damage and has no obvious side effects on the general growth of experimental mice, providing an ideal animal model for studying the pathological mechanism of hyperuricemia and screening anti-hyperuricemia renal damage drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1This is a graph of blood uric acid levels in mice in each group in Example 1;
[0036] Figure 2 This is the uric acid standard curve diagram of Example 2;
[0037] Figure 3 This is a graph of uric acid content in mouse serum in Example 3. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. The specific conditions not specified in the embodiments are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0039] Example 1
[0040] Adaptive feeding of mice: 40 SPF-grade male Kunming mice weighing 18-22 g with good growth and good health were selected as test subjects; a feeding environment with a suitable feeding temperature of 22-26°C and a humidity of 50-70% was provided, and food and water were freely available for 1 week.
[0041] Drug preparation: Yeast extract and hypoxanthine are prepared into a suspension with a 0.5% mass concentration sodium carboxymethyl cellulose aqueous solution, and the volume concentration of the suspension is 75 mg / mL, which contains 37.5 mg / mL hypoxanthine and 0.625 g / mL yeast extract; potassium oxonate suspension is prepared with a 0.5% mass concentration sodium carboxymethyl cellulose aqueous (CMC-Na) solution, and the volume concentration of the potassium oxonate suspension is 60 mg / mL.
[0042] Administration: 40 experimental mice were randomly divided into 4 groups, 10 mice in each group, namely blank group, model group A, model group B and model group C. All groups were provided with the same diet and drinking water, and all were free to eat. During the modeling experiment, the blank group was gavaged and intraperitoneally injected with 0.5% CMC-Na solution every day; the model group A was gavaged with yeast extract and intraperitoneally injected with potassium oxonate suspension every day; the model group B was gavaged with hypoxanthine yeast extract suspension and intraperitoneally injected with potassium oxonate suspension every day; the model group C was gavaged with hypoxanthine and intraperitoneally injected with potassium oxonate solution and 0.5% CMC-Na solution every day. The dosage of yeast extract was 5-10g / kg·d, the dosage of hypoxanthine was 300-600mg / kg·d, and the dosage of potassium oxonate was 300mg / kg·d. The amount of gavage and intraperitoneal injection in each group was the same, and it lasted for 14 days.
[0043] The specific process of blood uric acid content detection is:
[0044] Before the last administration of the modeling agent, the experimental mice were fasted but not watered for 12 hours. One hour after the administration of the modeling agent, the blood was collected from the eyeballs of the anesthetized mice and placed on ice for 1 hour. The supernatant was collected and placed in a centrifuge tube. The pretreatment was boiling for 10 minutes, adding 4 times the volume of water, vortexing, and centrifuging to determine the uric acid content in the supernatant.
[0045] Uric acid detection method adopts HPLC method. The specific parameters are as follows: chromatographic conditions: C18 column (250mm×4.6mm, 5μm), detection wavelength set to 280nm, flow rate 1.0mL / min, column temperature 30℃, injection volume 20μL; mobile phase is water-methanol system, phase A: 95% water, 5% methanol, 0.1% acetic acid; phase B: 100% methanol, 0.1% acetic acid.
[0046] HPLC program elution conditions
[0047]
[0048] result
[0049] according to Figure 1 As shown: Compared with the uric acid content of the blank group (170.62 μmol / L), the uric acid content of model group B increased most significantly (P < 0.05), with statistical significance, from 62.2% to 276.76 μmol / L. Intragastric administration of yeast extract combined with hypoxanthine in this group can provide a high-purine food source, and intraperitoneal injection of potassium oxonate can provide a uricase inhibitor to obtain a stable HUA model.
[0050] Example 2
[0051] Adaptive feeding of mice: 40 SPF male Kunming mice weighing 18-22 g with good growth and good health were selected as test subjects. A suitable feeding environment with a temperature of 22-26°C and a humidity of 50-70% was provided, and food and water were freely available for 1 week.
[0052] Drug preparation: Yeast extract and hypoxanthine are prepared into a suspension with a 0.5% mass concentration sodium carboxymethyl cellulose aqueous solution, and the volume concentration of the suspension is 75 mg / mL, which contains 37.5 mg / mL hypoxanthine and 0.625 g / mL yeast extract; potassium oxonate suspension is prepared with a 0.5% mass concentration sodium carboxymethyl cellulose aqueous solution, and the volume concentration of the potassium oxonate suspension is 60 mg / mL.
[0053] Administration: 40 experimental mice were randomly divided into 4 groups, 10 mice in each group, namely blank group, model group A, model group B and model group C. All groups were provided with the same diet and drinking water, and all were free to eat. During the modeling experiment, the blank group was gavaged and intraperitoneally injected with 0.5% CMC-Na solution every day; the model group A was gavaged with yeast extract and intraperitoneally injected with potassium oxonate solution every day; the model group B was gavaged with hypoxanthine yeast extract suspension and intraperitoneally injected with potassium oxonate solution every day; the model group C was gavaged with hypoxanthine and intraperitoneally injected with potassium oxonate solution and 0.5% CMC-Na solution every day. The dosage of yeast extract was 5-10g / kg·d, the dosage of hypoxanthine was 300-600mg / kg·d, and the dosage of potassium oxonate was 300mg / kg·d. The amount of gavage and intraperitoneal injection in each group was the same, and it lasted for 14 days.
[0054] During the modeling experiment, the blood uric acid content of the experimental mice was tested every week. The specific process is as follows:
[0055] The specific operation is as follows: mice were fasted but not watered for 12 hours before blood collection. After the modeling agent was given for 1 hour, the mice were fixed with a restrainer, and the middle part of the tail was disinfected with alcohol. After evaporation, the tail vein was punctured with a 4.5 (0.45×15mm) needle. The direction of the needle was from the tip of the mouse tail to the base. A 10μL pipette was used to draw about 30μL in small amounts and multiple times into the first centrifuge tube weighed in advance. The first centrifuge tube was centrifuged at 12000rpm for 10min, and boiled in a water bath for 10min. After instant centrifugation, serum A was obtained. Distilled water 3 to 4 times the volume of serum A was added, vortexed for 2min, centrifuged at 12000rpm for 10min, and 40μL of sample B was uniformly drawn into a second centrifuge tube of 1.5mL. Phenol chloroform with an equal volume to sample B was added, vortexed for 2min, and centrifuged at 12000rpm for 10min to obtain supernatant C. Supernatant C was transferred to a sample injection vial containing an inner insert for testing.
[0056] Uric acid detection method adopts HPLC method. The specific parameters are as follows: chromatographic conditions: C18 column (250mm×4.6mm, 5μm), detection wavelength set to 280nm, flow rate 1.0mL / min, column temperature 30℃, injection volume 20μL; mobile phase is water-methanol system, phase A: 95% water, 5% methanol, 0.1% acetic acid; phase B: 100% methanol, 0.1% acetic acid.
[0057] result
[0058] like Figure 2As shown, the standard curve obtains the regression equation y=18.671x+12.502 (R2=0.9997), and in the range of 3-400 μmol / L, the uric acid content and the absorption value have a good linear relationship. The uric acid detection limit obtained by the blood uric acid content detection method of the present invention is 0.92 μmol / L, and the quantitative limit is 1.70 μmol / L. The R2 of uric acid standards processed in different batches is greater than 0.999, and the detection limit is low, which can meet the inspection requirements of mouse blood uric acid.
[0059] The blood uric acid content detection method of the present invention was used to treat mouse uric acid samples, and uric acid standard was added to calculate the recovery rate. The results are shown in Table 2. The recovery rate of uric acid in the sample was in the range of 88.66% to 105.61%, and the relative standard deviation was 9.31%. The method has high sensitivity and accuracy and is suitable for determining the uric acid content in mouse blood.
[0060] Table 2 Recovery rates of samples with different concentrations
[0061]
[0062] Example 3
[0063] Adaptive feeding of mice: 24 SPF male Kunming mice weighing 18-22 g with good growth and good health were selected as test subjects. A suitable feeding environment with a temperature of 22-26°C and a humidity of 50-70% was provided, and food and water were freely available for 1 week.
[0064] Drug preparation: Yeast extract and hypoxanthine are prepared into a suspension with a 0.5% mass concentration sodium carboxymethyl cellulose aqueous solution, and the volume concentration of the suspension is 75 mg / mL, which contains 37.5 mg / mL hypoxanthine and 0.625 g / mL yeast extract; potassium oxonate suspension is prepared with a 0.5% mass concentration sodium carboxymethyl cellulose aqueous solution, and the volume concentration of the potassium oxonate suspension is 60 mg / mL.
[0065] Administration: 24 experimental mice were randomly divided into 2 groups, 8 mice in each group, namely blank group (CK), model group (HUA), and allopurinol group (AP). All groups were provided with the same diet and drinking water, and all were free to eat. During the modeling experiment, the blank group was gavaged and intraperitoneally injected with 0.5% CMC-Na solution every day; the other groups were gavaged with hypoxanthine yeast extract suspension and intraperitoneally injected with potassium oxonate solution every day. After an interval of 1h, the blank group and the model group were gavaged with 0.5% CMC-Na solution, and the allopurinol group was gavaged with allopurinol.
[0066] The mice were fasted but not watered for 12 hours before blood collection. One hour after the modeling drug was given, the blood was collected from the eyeballs of the anesthetized mice and placed on ice for 1 hour. The supernatant was collected and placed in a centrifuge tube. The pretreatment was boiling for 10 minutes, adding 4 times the volume of water, vortexing, and centrifuging to determine the uric acid content in the supernatant.
[0067] Uric acid detection method adopts HPLC method. The specific parameters are as follows: chromatographic conditions: C18 column (250mm×4.6mm, 5μm), detection wavelength set to 280nm, flow rate 1.0mL / min, column temperature 30℃, injection volume 20μL; mobile phase is water-methanol system, phase A: 95% water, 5% methanol, 0.1% acetic acid; phase B: 100% methanol, 0.1% acetic acid.
[0068] like Figure 3 As shown in the figure, compared with the CK group (219.57 μM), the uric acid level of mice in the HUA group increased significantly to 405.54 μM, an increase of 1.85 times, proving that the model was successful. The positive drug AP treatment group showed a very significant uric acid-lowering effect, and the uric acid content decreased to 98.23 μM.
[0069] The above are only preferred embodiments of the present invention, and do not limit the patent scope of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the patent protection scope of the present invention.
Claims
1. A method for constructing a mouse hyperuricemia model, characterized in that: The construction method comprises the following steps: Using yeast extract, hypoxanthine and potassium oxonate as modeling agents, the experimental mice were subjected to a modeling experiment lasting 14 to 21 days to obtain a hyperuricemia mouse model; During the modeling experiment, the blood uric acid content of the experimental mice was tested every week.
2. The method for constructing a mouse hyperuricemia model according to claim 1, characterized in that: The dosage of the yeast extract is 5-10 g / kg·d, the dosage of hypoxanthine is 300-600 mg / kg·d, and the dosage of potassium oxonate is 280-320 mg / kg·d.
3. The method for constructing a mouse hyperuricemia model according to claim 1, characterized in that: The yeast extract and hypoxanthine are both administered by intragastric gavage once a day; and the potassium oxonate is administered by intraperitoneal injection once a day.
4. The method for constructing a mouse hyperuricemia model according to claim 3, characterized in that: Before intragastric administration, the yeast extract and hypoxanthine are prepared into a suspension using sodium carboxymethyl cellulose aqueous solution as solvent. The suspension has a volume concentration of 70-80 mg / mL and contains 35-40 mg / mL hypoxanthine and 0.583-0.667 g / mL yeast extract.
5. The method for constructing a mouse hyperuricemia model according to claim 3, characterized in that: Before the potassium oxonate is administered by intraperitoneal injection, the potassium oxonate is prepared into a potassium oxonate suspension using a sodium carboxymethyl cellulose aqueous solution as a solvent, and the volume concentration of the potassium oxonate suspension is 50 to 70 mg / mL.
6. The method for constructing a mouse hyperuricemia model according to claim 4 or 5, characterized in that: The mass concentration of sodium carboxymethyl cellulose in the sodium carboxymethyl cellulose aqueous solution is 0.3-0.8%.
7. The method for constructing a mouse hyperuricemia model according to claim 1, characterized in that: The experimental mice were SPF grade male Kunming mice, weighing 18-30 g; The feeding conditions of the experimental mice are as follows: the feeding environment temperature is 22-26° C., and the feeding environment humidity is 50-70%.
8. The method for constructing a mouse hyperuricemia model according to claim 1, characterized in that: The specific process of the blood uric acid content detection is: Performing minimally invasive blood sampling on the tail of the test mouse to obtain a blood sample, and then centrifuging the blood sample to obtain a sample to be tested; The uric acid of the samples was detected by HPLC.
9. The method for constructing a mouse hyperuricemia model according to claim 8, characterized in that: The specific operation process of performing minimally invasive blood sampling on the tail of the test mouse to obtain a blood sample, and then centrifuging the blood sample to obtain the sample to be tested is as follows: The experimental mice were fasted but not watered for 12 to 18 hours before blood collection. After the modeling agent was given for 1 to 2 hours, the experimental mice were fixed, the middle part of the tail was disinfected with alcohol, and the tail vein was punctured with a needle after evaporation. The direction of the needle insertion was from the tip of the mouse tail to the base. 15 to 30 μL of blood sample was drawn into the first centrifuge tube weighed in advance with a 10 μL pipette. The first centrifuge tube was centrifuged at 12000 to 14000 rpm for 10 to 20 minutes and boiled in water for 10 to 20 minutes. The blood was obtained after instant centrifugation. Clear A, add 3 to 4 times the volume of distilled water of serum A to the first centrifuge tube, vortex for 2 to 4 minutes, centrifuge at 12000 to 14000 rpm for 10 to 20 minutes, draw 30 to 50 μL of sample B into the second centrifuge tube, add phenol chloroform with the same volume as sample B, vortex mix for 2 to 4 minutes, centrifuge at 12000 to 14000 rpm for 10 to 20 minutes to obtain supernatant C, transfer supernatant C to the injection vial containing the inner insert to obtain the sample to be tested.
10. The method for constructing a mouse hyperuricemia model according to claim 9, characterized in that: The specific parameters for the HPLC method for uric acid detection of the sample to be tested are as follows: Chromatographic conditions: C18 column, detection wavelength set at 270-290 nm, flow rate 0.8-1.2 mL / min, column temperature 30°C, injection volume 18-20 μL; mobile phase is water-methanol system, phase A: 95% water, 5% methanol, 0.1% acetic acid; phase B: 100% methanol, 0.1% acetic acid; gradient elution program is shown in Table 1: Table 1 HPLC program elution conditions
Citation Information
Patent Citations
Duplication method of rat continuous hyperuricemia model
CN108030784A
Building method of acute hyperuricemia renal damage mouse model
CN108785312A
Method for analyzing uricase in rat plasma through HPLC method
CN110308232A
Application of ampelopsis grossedentata flavone in preparation of uric acid reducing medicine
CN116196362A
Cited By
Hypertension mouse model and construction method and application thereof
CN120021587A
Construction method of hyperuricemia animal model
CN120283711A
Hyperuricemia modeling method based on combination of yeast feed and medicines
CN121220423A
